跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
利比 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Recombinant Human Interferon Beta 1a Solution for Injection
Approved
生物制品
Recombinant Human Interferon Beta 1a Solution for Injection
Merck Europe BV
🇨🇳 National Medical Products Administration
Approval Date
Oct 8, 2019
Approval ID
7LeagUWjYbO
Company
Merck Europe BV
Type
生物制品
Approval Details
Approval Id
7LeagUWjYbO
Approval Number
S20130073
Generic Name
重组人干扰素β1a注射液
Generic Name En
Recombinant Human Interferon Beta 1a Solution for Injection
Trade Name
利比
Drug Type
生物制品
Dosage Form
注射剂
Strength
1.2×10^7IU/0.5ml/支(44μg)
Reg Date
2019-10-08
Expired Date
2024-10-07
Company Name
Merck Europe BV
Company Address
Gustav Mahlerplein 102,1082 MA Amsterdam, The Netherlands
Production Company Name
merck serono s.p.a.
Production Company Address
Via delle Magnolie 15, Zona Industriale di Modugno, 70026 Modugno(BA) Italy
Company Detail Path
/organization/merck-europe-bv
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Oct 8, 2019
Approval ID
7LeagUWjYbO
Type
生物制品
Back to NMPA Approvals